Capitalizing on Innovation: An In-Depth Analysis of the MLSC Tax Incentive Program and the Massachusetts R&D Credit Framework

The Massachusetts Life Sciences Center (MLSC) Tax Incentive Program is a competitive state-administered initiative that provides certified life sciences companies with a diverse menu of refundable and non-refundable tax benefits in exchange for meeting specific job creation and retention targets. It serves as a strategic fiscal tool to offset the high costs associated with the research, development, and commercialization lifecycle while cementing the Commonwealth’s position as a global leader in the life sciences sector.1

The Massachusetts life sciences ecosystem is not a product of chance but rather the result of a deliberate, multi-decade legislative strategy designed to foster a high-concentration hub of scientific innovation. At the heart of this strategy is the Life Sciences Tax Incentive Program, a sophisticated mechanism that bridges the gap between early-stage scientific discovery and commercial-scale manufacturing. By aligning tax relief with economic development, the Commonwealth has created a symbiotic relationship where private sector growth directly contributes to public-sector goals of employment and regional development.4 Understanding this program requires a comprehensive examination of its administrative structure, its relationship with the broader Massachusetts Research and Development (R&D) tax credit, and the specific guidance issued by the Department of Revenue (DOR) that governs the technical application of these laws.

The Administrative Architecture of the MLSC

The Life Sciences Tax Incentive Program is administered by the Massachusetts Life Sciences Center (MLSC), a quasi-public agency established under the Life Sciences Act of 2008. The MLSC is charged with implementing the Commonwealth’s $1 billion, multi-year investment in the life sciences industry, which was significantly expanded by subsequent legislation in 2018 and most recently in 2024 through “An Act relative to strengthening Massachusetts’ economic leadership”.2 This administrative structure is unique because it separates the technical tax administration, handled by the Department of Revenue, from the strategic certification and award process, handled by the MLSC.

For a company to access these incentives, it must first be “certified” as a life sciences company by the MLSC. This certification is not a passive status but a competitive designation granted based on a company’s ability to create and retain high-quality jobs in Massachusetts. The MLSC evaluates applicants based on their research focus, commercial potential, and, most importantly, their commitment to the Commonwealth’s workforce.4

Legislative Evolution and Funding Mandates

The program’s history is defined by a series of legislative expansions that reflect the increasing maturity of the life sciences sector. The original 2008 Act provided $25 million in annual tax incentives. The 2018 reauthorization increased this to $30 million, and the 2024 Economic Leadership bill further increased the statutory cap to $40 million for taxable years beginning on or after January 1, 2024.1

This funding evolution underscores the Commonwealth’s proactive stance in competing with other global biotech hubs. The 2024 legislation also introduced targeted reforms, such as reducing the job retention commitment period from five years to three years in certain instances and expanding the program’s scope to explicitly include health-related artificial intelligence and preventative medicine.8

The Taxonomy of the Life Sciences Tax Incentive Portfolio

The Life Sciences Tax Incentive Program is often misinterpreted as a single credit. In reality, it is a “menu” of approximately nine to ten distinct incentives that companies can mix and match to suit their financial profile and operational stage.2 Once the MLSC determines a total award amount for a company based on its job creation commitment, the company allocates that award across various incentives.

The Research Credit Dichotomy: Section 38M vs. Section 38W

One of the most complex aspects of the program is the intersection of the general Massachusetts R&D tax credit and the specialized life sciences credits. Massachusetts offers two primary research credits under Chapter 63 of the General Laws:

1. The General Research Credit (M.G.L. c. 63, § 38M)

This is the standard R&D credit available to all business corporations in Massachusetts. It is modeled after the federal Internal Revenue Code (IRC) Section 41 and typically provides a 10% credit for qualified research expenses (QREs) that exceed a base amount.10 While generally non-refundable for most corporations, the Life Sciences Tax Incentive Program allows certified companies to request a refund of 90% of their unused, available excess 38M research credits.1

2. The Life Science Research Credit (M.G.L. c. 63, § 38W)

This is a separate, specialized credit available only to certified life sciences companies and only to the extent specifically authorized by the MLSC.11 Unlike the 38M credit, which is calculated based on statutory formulas that include an Alternative Simplified Method (ASM), the 38W credit requires a computation using a fixed-base percentage determined under the IRC as of August 12, 1991.11 Furthermore, the 38W credit is strictly non-refundable, although it can be carried forward for 15 years.8

The strategic implication of this dichotomy is profound. A pre-revenue startup might prefer to allocate its MLSC award to make its 38M credits refundable to provide immediate liquidity. Conversely, a profitable pharmaceutical company might choose to utilize 38W credits to offset clinical trial-related expenditures that might not qualify under the more rigid 38M definitions.1

Capital and Infrastructure Incentives

The Life Sciences Investment Tax Credit (ITC), provided under G.L. c. 62, § 6(m) and c. 63, § 38U, is a primary driver for companies building manufacturing facilities or expanding laboratory space. This credit is equal to 10% of the cost of qualifying property (e.g., equipment, buildings) used exclusively in Massachusetts.1 This rate is significantly higher than the standard 3% ITC available to general manufacturers.16

Key features of the Life Sciences ITC include:

• Refundability: Up to 90% of the unused credit may be refunded if authorized by the MLSC.1
• Property Scope: Includes tangible personal property and other tangible property with a useful life of three years or more.15
• Exclusivity: Corporations taking the 10% Life Sciences ITC cannot also take the standard 3% ITC or the Low Income Housing Credit for the same property.13

Specialized Relief: FDA User Fees and Orphan Drug Deductions

The program addresses specific regulatory costs unique to the industry. The FDA User Fees Credit (G.L. c. 62, § 6(n) and c. 63, § 31M) provides a 100% credit for fees paid to the FDA for applications to manufacture human drugs in Massachusetts, provided that more than 50% of the R&D costs for the drug were incurred in the state.1 Like the ITC, 90% of the unused credit is refundable.1

For companies targeting rare diseases, the Deduction for Qualified Orphan Drug Expenses (G.L. c. 63, § 38V) allows a deduction for clinical testing expenses that may not be fully deductible under standard rules, incentivizing the development of therapies for small patient populations.2

Operational and Sales Incentives

The program also provides relief for day-to-day operations and long-term tax planning:

• Net Operating Loss (NOL) Extension: While standard MA corporate rules allow a 5-year carryforward for NOLs, certified life sciences companies may carry forward these losses for 15 years.1
• Sales Tax Exemption: Certified companies may be exempt from sales and use tax on property used directly in R&D.2
• Life Sciences Refundable Jobs Credit: This is an additional incentive specifically for companies committing to at least 50 net new permanent full-time positions. The credit amount is determined by the MLSC in consultation with the DOR and is 90% refundable.1

Revenue Office Guidance and Technical Application

The technical administration of these incentives is governed by a series of Technical Information Releases (TIRs) and regulations issued by the Massachusetts Department of Revenue. These documents provide the “fine print” that determines how the law applies in practice.

TIR 08-23: The Interpretive Framework

Issued shortly after the program’s inception, TIR 08-23 serves as the foundational guidance for the Life Sciences Tax Incentive Program. It clarifies that the incentives are available only to certified companies and only to the extent authorized by the MLSC and approved by the Secretary of Administration and Finance.15

This TIR established several critical rules:

• Disallowance of Deductions: If a company claims a credit for a cost (such as FDA user fees), the otherwise allowable deduction for that same cost is disallowed to prevent “double benefits”.1
• Property Definitions: For the ITC, the definition of “qualifying property” is identical to that found in c. 63, § 31A, ensuring consistency across the corporate excise code.15
• Election of Refund: Companies must affirmatively opt into the refund option. If they do, they waive the right to carry forward the credit to future years.14

TIR 13-6: Recapture and Compliance

One of the most important administrative guides is TIR 13-6, which details the calculation and recapture of incentives from companies that fail to meet their commitments.14 The MLSC is required by statute to investigate companies and revoke certification if their conduct is “materially at variance” with their original proposal.

The recapture rules in TIR 13-6 are rigorous:

• Trigger Date: Recapture is calculated from the first day of the taxable year in which the material variance began.14
• Pro-rata Calculations: For job commitments, the DOR may pro-rate the recapture based on the level of non-compliance. For example, if a company achieves only 50% of its target over a multi-year period, it may be required to return a proportionate amount of the benefit.19
• Anti-Laundering Provision: A decertified company cannot use non-refundable credit carryforwards to offset its recapture tax liability. This ensures that the clawback process is effective and cannot be avoided by utilizing other tax attributes.14

2025 Updates: TIR 25-3 and Financial Institutions

In a landmark shift, TIR 25-3 (May 2025) addressed the eligibility of financial institutions to claim the Research Tax Credit under G.L. c. 63, § 38M.10 This guidance follows the Appellate Tax Board decision in State Street Corporation v. Commissioner of Revenue, which held that financial institutions are indeed “business corporations” for the purposes of the research credit.20 While not exclusive to the life sciences, this ruling expands the pool of entities that can participate in R&D activity within the state and clarifies the tax position of institutional partners in the life sciences ecosystem.10

Mechanics of Award Calculation: The Per-Job Formula

The MLSC uses a formulaic approach to determine the size of a tax award. This formula is designed to incentivize not just job creation, but high-value jobs in specific geographic areas.1

Base Credit and Bonuses

The standard award is calculated on a “per net new job” basis. A company’s total available credit is the product of its job commitment and the calculated per-job rate.1

Under this formula, a startup building a manufacturing plant in Western Massachusetts could theoretically receive an award of up to $33,000 per new employee hired.1 This tiered system allows the MLSC to direct resources toward smaller, higher-risk companies and regions that are outside the traditional Boston/Cambridge hub.

Filing Requirements and the Lifecycle of a Credit

Claiming the credit is a multi-step process that involves coordination between the company’s HR, R&D, and tax departments.

The Certification and Solicitation Cycle

The process begins with the MLSC’s annual solicitation, usually issued in mid-December with applications due in February.1 Companies must provide:

• Baseline Headcount: The number of permanent full-time employees (working $\geq$ 35 hours per week) as of December 31.1
• Hiring Commitment: The net new jobs to be created in the following calendar year.3
• Tax Allocation Plan: A breakdown of which specific incentives the company intends to claim.1

Filing Schedule RLSC and CMS

Once an award is granted, the company must wait until the state’s next fiscal year (beginning July 1) to claim the incentive on its tax return.2 For a calendar-year taxpayer, this often means extending the return to align with the award cycle.

The primary forms used are:

• Schedule RLSC (Refundable Life Science Credit): This form is used to report the total credits authorized by the MLSC and to calculate the refundable portion (typically 90% of the excess).21
• Credit Manager Schedule (CMS): This is the master schedule where all Massachusetts credits are aggregated. Companies must enter the unique certificate number provided by the MLSC to claim the credit.11

Case Study: NovaGenics Therapeutics

To illustrate the program’s impact, consider “NovaGenics Therapeutics,” a clinical-stage biotechnology company with 45 employees headquartered in Worcester. NovaGenics is expanding its R&D labs and building a small-scale manufacturing suite for its upcoming Phase III clinical trials.

Step 1: The Commitment

NovaGenics applies to the MLSC, committing to hire 15 net new permanent full-time employees in the 2025 calendar year. Of these 15 jobs, 10 are in manufacturing.

Step 2: Award Calculation

Based on NovaGenics’ profile, the MLSC calculates the award as follows:

• For 5 R&D Jobs: Base ($18k) + Small Co ($5k) = $23,000 per job. (Total: $115,000)
• For 10 Manufacturing Jobs: Base ($18k) + Small Co ($5k) + Mfg Bonus ($5k) = $28,000 per job. (Total: $280,000)
• Total Award Amount: $395,000.1

Step 3: Allocation Strategy

NovaGenics allocates its $395,000 award to maximize its cash flow and offset its specific expenses:

1. Refundable ITC ($200,000): NovaGenics plans to spend $2 million on new manufacturing equipment. This 10% credit ($200k) will offset its current tax liability to the $456 minimum tax floor, and the company will receive 90% of the remainder as a cash refund.1
2. Refundable § 38M Research Credit ($150,000): The company already has $200,000 in unused research credits from its heavy R&D spending. By allocating $150,000 of its MLSC award to this incentive, it can convert these non-refundable credits into a $135,000 check (90% of $150k).1
3. FDA User Fees Credit ($45,000): NovaGenics anticipates paying its New Drug Application (NDA) fees in the coming year and uses the remaining award to cover this 100% credit.1

Step 4: Compliance and Retention

NovaGenics hires the 15 employees by December 31, 2025. It must now retain these 15 employees, plus its original 45-person baseline (total 60 employees), through at least December 31, 2027. Failure to maintain this headcount would trigger the recapture provisions of TIR 13-6.3

Economic Impact and Regional Distribution

The MLSC Tax Incentive Program has served as a catalyst for geographic equity within the Massachusetts economy. While the Boston and Cambridge submarkets remain the global “ground zero” for biotech, the program’s bonuses for Gateway Cities and remote counties have successfully pushed expansion into other regions.4

Cumulative Statistics (2008 – 2024)

The impact of the program is best understood through its cumulative performance data.

In Fiscal Year 2024, the MLSC awarded $24.5 million in tax incentives to 22 companies, which is expected to create 1,519 new industry jobs.6 This regional shift is crucial for the long-term sustainability of the industry, as it utilizes the diverse workforce and lower operational costs of cities like Worcester, Lowell, and Springfield, while maintaining proximity to the research powerhouses of Greater Boston.6

Risk Management: The Clawback and Investigation Process

For companies participating in the program, the primary risk is de-certification. The MLSC maintains a strict monitoring protocol based on annual reports. The “material variance” standard is the legal threshold for revocation.5

The 70% Compliance Threshold

The MLSC uses a “pro-business but accountable” approach to monitoring:

• Over 70% Achievement: Companies that achieve at least 70% of their job target for two consecutive years are generally considered in compliance. If they fall slightly short (between 70-89%), they remain certified but may be barred from applying for new awards until they reach 90% of their existing target.5
• The Investigation Zone (40% – 70%): If a company falls into this range, the MLSC conducts an investigation. If the shortfall is due to external factors (e.g., clinical trial failure, economic downturn), the MLSC may grant a one-year extension.5
• Failure Zone (< 40%): Companies that fail to reach even 40% of their target are typically de-certified immediately, triggering the full recapture process with the Department of Revenue.5

This structured oversight ensures that the Commonwealth’s investment remains tied to actual economic performance, providing a level of transparency and accountability that is often cited as a model for other state-level incentive programs.24

Conclusion: The Strategic Future of the Life Sciences Ecosystem

The Massachusetts Life Sciences Center Tax Incentive Program is more than a simple set of tax credits; it is a fundamental pillar of the state’s economic identity. By creating a competitive, award-based system that prizes job creation over simple expenditure, Massachusetts has ensured that its tax relief is directly tied to the growth of its human capital.

The program’s intersection with the broader Massachusetts R&D tax credit framework provides a level of fiscal flexibility that is particularly well-suited for the “long-game” of life sciences innovation. Whether through the 90% refundability of § 38M credits for cash-strapped startups or the 15-year carryforward of § 38W credits for maturing enterprises, the system is designed to support a company at every stage of its growth.

As the program moves toward its 2033 sunset with an increased $40 million annual cap and a new focus on AI-driven medicine, its role will only become more critical. For life sciences companies looking to locate or expand in the Commonwealth, navigating these incentives is not just a matter of compliance—it is a strategic imperative that can provide the necessary capital to turn today’s research into tomorrow’s life-saving therapies. The clear guidance provided by the Department of Revenue in TIRs 08-23 and 13-6, combined with the MLSC’s transparent award process, ensures that this program will continue to be a cornerstone of the world’s most vibrant life sciences hub.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/